Background And Objectives: The diagnosis of hypertension among hemodialysis patients by predialysis or postdialysis blood pressure (BP) recordings is imprecise and biased and has poor test-retest reliability. The use of intradialytic BP measurements to diagnose hypertension is unknown.
Design, Setting, Participants, & Measurements: A diagnostic-test study was done with interdialytic ambulatory BP as reference standard. Index BP recordings tested were: predialysis (method 1), postdialysis (method 2), intradialytic (method 3), intradialytic including predialyis and postdialysis (method 4), and the average of predialysis and postdialysis (method 5). Each index BP was recorded over six consecutive dialysis treatments.
Results: There were differences among index BP measurements in reproducibility, bias, precision, and accuracy. Method 4 was the most reproducible (intraclass correlation coefficient = 0.70 for systolic and diastolic BP). All 5 measurement methods overestimated 44-h ambulatory systolic BP. Methods 2, 3, or 4 overestimated ambulatory systolic BP by only a small amount. Method 4 was the most precise and accurate. For diagnosis of hypertension, BP cut-point by method 4 of 135/75 mmHg, had a sensitivity of 90.4% and specificity of 75.9% for systolic BP (area under ROC curve 0.90). Median cut-off systolic BP of 140 mmHg from a single dialysis provides approximately 80% sensitivity and 80% specificity in diagnosing systolic hypertension; a median cut-off diastolic BP of 80 mmHg provides approximately 75% sensitivity and 75% specificity in diagnosing diastolic hypertension.
Conclusions: Consideration of intradialytic BP measurements together with predialysis and postdialysis BP measurements improves the reproducibility, bias, precision, and accuracy of BP measurement compared with predialysis or postdialysis measurements.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518788 | PMC |
http://dx.doi.org/10.2215/CJN.01510308 | DOI Listing |
BMC Nephrol
January 2025
Medical career, Faculty of Health Sciences, Universidad Técnica de Ambato, Ambato, Ecuador.
Background: High blood pressure is a prevalent condition in patients with chronic kidney disease on hemodialysis. Adequate control of high blood pressure is essential to reducing deaths in this group. The present study aimed to observe mortality prospectively in a group of patients in hemodialysis and hemodiafiltration programs in whom the use of antihypertensives was optimized with the point-of-care dry weight (POC-DW) technique.
View Article and Find Full Text PDFActa Cardiol
December 2024
Division of Nephrology, Department of Internal Medicine, University of Liège Hospital (ULiège CHU), Liège, Belgium.
Background: Blood pressure (BP) control in haemodialysis (HD) patients is essential. Peri-dialytic BP levels do not accurately diagnose hypertension or predict the cardiovascular (CV) mortality.
Methods: In this study, we recruited 43 adult patients who had been on chronic HD for ≥3 months.
Urologiia
November 2024
Nephrology department, Faculty of Medicine, Ain-Shams University, Cairo, Egypt.
Purpose: In this study, we compared the effects of a single patient dialysis fluid delivery system (SPDDS) against a continuous dialysis fluid delivery system (CDDS) on inflammatory markers and endotoxemia in a population of patients receiving routine hemodialysis (HD) at Ain Shams University.
Materials And Methods: Eighty prevalent HD patients, ages 18 to 60, who were clinically stable and receiving thrice weekly dialysis treatments via an arteriovenous fistula were the subjects of a cross-sectional research. The study excluded patients with double lumen venous catheters used for hemodialysis, acute infections, cancer, and chronic liver disease.
Clin Pharmacokinet
November 2024
Gilead Sciences, Inc., Foster City, CA, 94404, USA.
Background And Objective: Remdesivir is a nucleotide analog prodrug approved for the treatment of COVID-19. This study evaluated the pharmacokinetics and safety of remdesivir and its metabolites (GS-704277 and GS-441524) in participants with varying degrees of renal impairment. Results of this phase I study, along with those of a phase III study, contributed to an extension of indication for remdesivir in the USA and Europe for use in patients with COVID-19 with all stages of renal impairment, including those on dialysis, with no dose adjustment.
View Article and Find Full Text PDFCochrane Database Syst Rev
November 2024
Department of Medicine, Counties Manukau Health, Auckland, New Zealand.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!